Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Patient factors associated with hemoglobin A1C change with pioglitazone as adjunctive therapy in type 2 Diabetes Mellitus.

Tran MT, Delate T, Bachmann S.

Pharm Pract (Granada). 2008 Apr;6(2):79-87. Epub 2008 Jun 17.

2.

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.

Kashiwagi A, Kadowaki T, Tajima N, Nonaka K, Taniguchi T, Nishii M, Ferreira JC, Amatruda JM.

J Diabetes Investig. 2011 Oct 7;2(5):381-90. doi: 10.1111/j.2040-1124.2011.00120.x.

3.

Diabetes mellitus: new challenges and innovative therapies.

Sena CM, Bento CF, Pereira P, Seiça R.

EPMA J. 2010 Mar;1(1):138-63. doi: 10.1007/s13167-010-0010-9. Epub 2010 Mar 13.

4.

Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review.

Desouza CV, Shivaswamy V.

Clin Med Insights Endocrinol Diabetes. 2010;3:43-51. Epub 2010 Aug 3.

5.

Consensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetes.

Klonoff DC, Blonde L, Cembrowski G, Chacra AR, Charpentier G, Colagiuri S, Dailey G, Gabbay RA, Heinemann L, Kerr D, Nicolucci A, Polonsky W, Schnell O, Vigersky R, Yale JF; Coalition for Clinical Research-Self-Monitoring of Blood Glucose Scientific Board.

J Diabetes Sci Technol. 2011 Nov 1;5(6):1529-48.

7.

Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus.

Morrison F, Shubina M, Turchin A.

Arch Intern Med. 2011 Sep 26;171(17):1542-50. doi: 10.1001/archinternmed.2011.400.

8.

PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW.

Differentiation. 2011 Nov-Dec;82(4-5):220-36. doi: 10.1016/j.diff.2011.05.008. Epub 2011 Jun 8. Review.

9.

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.

Rodríguez A, Reviriego J, Karamanos V, del Cañizo FJ, Vlachogiannis N, Drossinos V; ECLA Study Group.

Cardiovasc Diabetol. 2011 Feb 11;10:18. doi: 10.1186/1475-2840-10-18.

10.

Treatment of dyslipidemia in patients with type 2 diabetes.

Vijayaraghavan K.

Lipids Health Dis. 2010 Dec 20;9:144. doi: 10.1186/1476-511X-9-144. Review.

11.
12.

Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells.

Zhang LH, Kamanna VS, Ganji SH, Xiong XM, Kashyap ML.

J Lipid Res. 2010 Aug;51(8):2211-22. doi: 10.1194/jlr.M004481. Epub 2010 Apr 6.

13.

EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage.

Püntmann I, Schmacke N, Melander A, Lindberg G, Mühlbauer B.

BMC Clin Pharmacol. 2010 Mar 16;10:5. doi: 10.1186/1472-6904-10-5.

14.

Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.

Musholt PB, Schöndorf T, Pfützner A, Hohberg C, Kleine I, Fuchs W, Hehenwarter S, Dikta G, Kerschgens B, Forst T.

J Diabetes Sci Technol. 2009 Nov 1;3(6):1442-50.

15.

Current and novel therapies for the treatment of nonalcoholic steatohepatitis.

van der Poorten D, George J.

Hepatol Int. 2007 Sep;1(3):343-54. doi: 10.1007/s12072-007-9011-8. Epub 2007 Jul 26.

16.

Safety and efficacy of rosiglitazone in the elderly diabetic patient.

Viljoen A, Sinclair A.

Vasc Health Risk Manag. 2009;5(1):389-95. Review.

17.

Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone.

Nakaya H, Summers BD, Nicholson AC, Gotto AM Jr, Hajjar DP, Han J.

Am J Pathol. 2009 Jun;174(6):2007-14. doi: 10.2353/ajpath.2009.080611. Epub 2009 May 12.

18.

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes.

Brunelli SM, Thadhani R, Ikizler TA, Feldman HI.

Kidney Int. 2009 May;75(9):961-8. doi: 10.1038/ki.2009.4. Epub 2009 Feb 4.

19.

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.

Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL.

Arch Intern Med. 2008 Oct 27;168(19):2070-80. doi: 10.1001/archinte.168.19.2070. Review.

20.

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

Dorkhan M, Frid A.

Vasc Health Risk Manag. 2007;3(5):721-31. Review.

Supplemental Content

Support Center